NYSE:TEVA Teva Pharmaceutical Industries - TEVA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Teva Pharmaceutical Industries Limited Please log in to your account or sign up in order to add this asset to your watchlist. $8.73 -0.07 (-0.80%) (As of 03/22/2023 12:00 AM ET) Add Compare Share Share Today's Range$8.73▼$9.0050-Day Range$8.36▼$11.3752-Week Range$6.78▼$11.44Volume6.91 million shsAverage Volume9.28 million shsMarket Capitalization$9.70 billionP/E RatioN/ADividend YieldN/APrice Target$10.78 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Teva Pharmaceutical Industries MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside23.5% Upside$10.78 Price TargetShort InterestHealthy2.30% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.28Based on 7 Articles This WeekInsider TradingSelling Shares$1.57 M Sold Last QuarterProj. Earnings Growth3.90%From $2.31 to $2.40 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.75 out of 5 starsMedical Sector769th out of 983 stocksPharmaceutical Preparations Industry368th out of 478 stocks 2.0 Analyst's Opinion Consensus RatingTeva Pharmaceutical Industries has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 3 buy ratings, 3 hold ratings, and 3 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.78, Teva Pharmaceutical Industries has a forecasted upside of 23.5% from its current price of $8.73.Amount of Analyst CoverageTeva Pharmaceutical Industries has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.30% of the outstanding shares of Teva Pharmaceutical Industries have been sold short.Short Interest Ratio / Days to CoverTeva Pharmaceutical Industries has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Teva Pharmaceutical Industries has recently decreased by 7.62%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTeva Pharmaceutical Industries does not currently pay a dividend.Dividend GrowthTeva Pharmaceutical Industries does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TEVA. Previous Next 1.8 News and Social Media Coverage News SentimentTeva Pharmaceutical Industries has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Teva Pharmaceutical Industries this week, compared to 5 articles on an average week.Search InterestOnly 24 people have searched for TEVA on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Teva Pharmaceutical Industries to their MarketBeat watchlist in the last 30 days. This is a decrease of -18% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Teva Pharmaceutical Industries insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,572,797.00 in company stock.Percentage Held by InsidersOnly 0.82% of the stock of Teva Pharmaceutical Industries is held by insiders.Percentage Held by Institutions50.39% of the stock of Teva Pharmaceutical Industries is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Teva Pharmaceutical Industries are expected to grow by 3.90% in the coming year, from $2.31 to $2.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Teva Pharmaceutical Industries is -4.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Teva Pharmaceutical Industries is -4.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioTeva Pharmaceutical Industries has a PEG Ratio of 2.48. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioTeva Pharmaceutical Industries has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Teva Pharmaceutical Industries (NYSE:TEVA) StockTeva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.Read More Receive TEVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter. Email Address TEVA Stock News HeadlinesMarch 22, 2023 | finance.yahoo.com3 No-Brainer Stocks to Buy With $10 Right NowMarch 18, 2023 | marketwatch.comFrom 2023 to 2029, Dabigatran Market InsightMarch 22, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 17, 2023 | marketwatch.comSmart Medication Inhalers Market Statistics and Industry Share Analysis Forecast 2023-2028March 17, 2023 | marketwatch.comHuman Reproductive Technologies Market Size, Share, Industry Analysis 2029March 16, 2023 | finanznachrichten.deART MEDICAL Ltd: ART MEDICAL Announces Partnership With Teva Israel to Bring Its Lifesaving Technology to Critical Care UnitsMarch 16, 2023 | americanbankingnews.comTeva Pharmaceutical Industries (NYSE:TEVA) Receives New Coverage from Analysts at StockNews.comMarch 15, 2023 | marketwatch.com2023-2028 Transdermal Skin Patches Market Growth and Size Analysis by Industry Experts | Latest Research ReportMarch 22, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 14, 2023 | finance.yahoo.com25 Biggest Pharmaceutical Companies in the WorldMarch 14, 2023 | marketwatch.comGlobal Respiratory Tract Infection Therapeutic Market Statistics and Industry Share Analysis Forecast 2023-2028March 14, 2023 | marketwatch.comAntivirals Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2028March 13, 2023 | finance.yahoo.comTeva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Early SettlementMarch 13, 2023 | finance.yahoo.comMcKinsey Consulted VA While Advising Opioid Makers to Target Agency for SalesMarch 13, 2023 | marketwatch.comMolecule Drug Discovery Market : Detailed Analysis of Industry, Attractive Valuation and Growth Forecast Up to 2029March 7, 2023 | marketwatch.comAzacitidine Market 2023 | Global Industry Report Forecast 2029March 5, 2023 | finance.yahoo.comBetter Generics Pharmaceutical Stock: Teva or Viatris?March 4, 2023 | seekingalpha.comTeva Pharmaceutical Industries Limited 2022 Q4 - Results - Earnings Call PresentationMarch 3, 2023 | finance.yahoo.com3 Generic Drug Stocks to Watch Amid Macro HeadwindsMarch 3, 2023 | marketwatch.comDiabetic Neuropathy Drugs Market Insights-Industry changing aspects, New Technologies and Forecast to 2028March 2, 2023 | finance.yahoo.comPropulsion of Asthma Pipeline as Novel and Extensive 95+ Therapies Likely to Enter in the Treatment Domain | DelveInsightMarch 1, 2023 | businesswire.comTeva Announces Successful Upsize and Pricing of $2,490,000,000 (equivalent) Sustainability-Linked Senior Notes and the Increase of the Maximum Tender Amount of its Debt Tender ...March 1, 2023 | finance.yahoo.comTeva Announces Successful Upsize and Pricing of $2,490,000,000 (equivalent) Sustainability-Linked Senior Notes and the Increase of the Maximum Tender Amount of its Debt Tender OfferMarch 1, 2023 | marketwatch.comPoly-Myalgia Rheumatica Treatment Market Industry Analysis, Estimates Size and Projections by 2029February 26, 2023 | marketwatch.comGlobal Digital Dose Inhalers Market Insights, Key Players and Top Factors Driving the Industry 2023 – 2030 By VMReportsFebruary 25, 2023 | marketwatch.comStress Management Supplements Market 2023 : Detailed analysis of Industry Potential Growth attractive Valuation and growth Forecast up to 2029February 24, 2023 | marketwatch.comMethotrexate Market 2023 : Global Industry Share, Key Dynamics and Forecast to 2028See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TEVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter. Email Address TEVA Company Calendar Last Earnings2/08/2023Today3/22/2023Next Earnings (Estimated)5/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:TEVA CUSIPN/A CIK818686 Webwww.tevapharm.com Phone(723) 914-8213Fax972-3923-4050Employees36,826Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.78 High Stock Price Forecast$14.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+23.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.12) Trailing P/E RatioN/A Forward P/E Ratio3.78 P/E Growth2.48Net Income$-2,353,000,000.00 Net Margins-15.76% Pretax Margin-20.54% Return on Equity28.06% Return on Assets5.93% Debt Debt-to-Equity Ratio2.20 Current Ratio1.05 Quick Ratio0.72 Sales & Book Value Annual Sales$14.93 billion Price / Sales0.65 Cash Flow$3.76 per share Price / Cash Flow2.32 Book Value$7.82 per share Price / Book1.12Miscellaneous Outstanding Shares1,110,900,000Free Float1,101,791,000Market Cap$9.70 billion OptionableOptionable Beta1.22 Key ExecutivesRichard FrancisPresident, Chief Executive Officer & DirectorEric DrapéExecutive Vice President-Global OperationsEli KalifChief Financial Officer & Executive Vice PresidentEric A. HughesChief Medical Officer, Executive VP-Global R&DKathleen VeitSenior VP-Global Compliance & Ethics OfficerKey CompetitorsUnited TherapeuticsNASDAQ:UTHRDr. Reddy's LaboratoriesNYSE:RDYJazz PharmaceuticalsNASDAQ:JAZZViatrisNASDAQ:VTRSApellis PharmaceuticalsNASDAQ:APLSView All CompetitorsInsiders & InstitutionsPictet North America Advisors SASold 845,718 shares on 3/22/2023Ownership: 0.007%Sven DethlefsSold 19,355 sharesTotal: $192,195.15 ($9.93/share)David Matthew StarkSold 16,491 sharesTotal: $163,755.63 ($9.93/share)Rockefeller Capital Management L.P.Bought 2,355 shares on 3/6/2023Ownership: 0.001%Sven DethlefsSold 59,655 sharesTotal: $589,987.95 ($9.89/share)View All Insider TransactionsView All Institutional Transactions TEVA Stock - Frequently Asked Questions Should I buy or sell Teva Pharmaceutical Industries stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 3 sell ratings, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TEVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TEVA, but not buy additional shares or sell existing shares. View TEVA analyst ratings or view top-rated stocks. What is Teva Pharmaceutical Industries' stock price forecast for 2023? 9 brokerages have issued 1 year price targets for Teva Pharmaceutical Industries' shares. Their TEVA share price forecasts range from $7.00 to $14.00. On average, they anticipate the company's share price to reach $10.78 in the next twelve months. This suggests a possible upside of 20.4% from the stock's current price. View analysts price targets for TEVA or view top-rated stocks among Wall Street analysts. How have TEVA shares performed in 2023? Teva Pharmaceutical Industries' stock was trading at $9.12 at the start of the year. Since then, TEVA shares have decreased by 1.9% and is now trading at $8.95. View the best growth stocks for 2023 here. When is Teva Pharmaceutical Industries' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023. View our TEVA earnings forecast. How were Teva Pharmaceutical Industries' earnings last quarter? Teva Pharmaceutical Industries Limited (NYSE:TEVA) issued its quarterly earnings results on Wednesday, February, 8th. The company reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.04. The firm earned $3.88 billion during the quarter, compared to analysts' expectations of $3.90 billion. Teva Pharmaceutical Industries had a negative net margin of 15.76% and a positive trailing twelve-month return on equity of 28.06%. What ETFs hold Teva Pharmaceutical Industries' stock? ETFs with the largest weight of Teva Pharmaceutical Industries (NYSE:TEVA) stock in their portfolio include iShares MSCI Israel ETF (EIS), VanEck Israel ETF (ISRA), VanEck Pharmaceutical ETF (PPH), ARK Israel Innovative Technology ETF (IZRL), iShares MSCI Intl Value Factor ETF (IVLU), Invesco RAFI Strategic Developed ex-US ETF (ISDX) and Goldman Sachs ActiveBeta International Equity ETF (GSIE) and What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings? Teva Pharmaceutical Industries issued an update on its FY23 earnings guidance on Wednesday, February, 8th. The company provided earnings per share guidance of $2.25-2.55 for the period, compared to the consensus earnings per share estimate of $2.52. The company issued revenue guidance of $14.8-15.4 billion, compared to the consensus revenue estimate of $15.19 billion. What is Kåre Schultz's approval rating as Teva Pharmaceutical Industries' CEO? 158 employees have rated Teva Pharmaceutical Industries Chief Executive Officer Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among the company's employees. What other stocks do shareholders of Teva Pharmaceutical Industries own? Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO). What is Teva Pharmaceutical Industries' stock symbol? Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA." Who are Teva Pharmaceutical Industries' major shareholders? Teva Pharmaceutical Industries' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Phoenix Holdings Ltd. (2.00%), Migdal Insurance & Financial Holdings Ltd. (1.94%), Clal Insurance Enterprises Holdings Ltd (1.66%), Abrams Capital Management L.P. (1.43%), Harel Insurance Investments & Financial Services Ltd. (1.36%) and Exor Capital LLP (1.35%). Insiders that own company stock include David Matthew Stark, Eli Shani, Eliyahu Sharon Kalif, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Pharmaceutical Co Ltd Takeda, Richard Daniell, Rosemary A Crane and Sven Dethlefs. View institutional ownership trends. How do I buy shares of Teva Pharmaceutical Industries? Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Teva Pharmaceutical Industries' stock price today? One share of TEVA stock can currently be purchased for approximately $8.95. How much money does Teva Pharmaceutical Industries make? Teva Pharmaceutical Industries (NYSE:TEVA) has a market capitalization of $9.94 billion and generates $14.93 billion in revenue each year. The company earns $-2,353,000,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis. How many employees does Teva Pharmaceutical Industries have? The company employs 36,826 workers across the globe. How can I contact Teva Pharmaceutical Industries? Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The official website for the company is www.tevapharm.com. The company can be reached via phone at (723) 914-8213, via email at kevin.mannix@tevapharm.com, or via fax at 972-3923-4050. This page (NYSE:TEVA) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.